# US 2008/0287403 A1 · Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287403 A1
- Document ID: US20080287403A1
- Status: Published application
- Kind: A1
- Application number: 12/125,313
- Filed: 2008-05-22
- Published: 2008-11-20
- Earliest claimed: 1999-08-30
- Assignees: Aventis Pharma Deutschland GmbH
- Inventors: Bernward Scholkens; Norbert Bender; Badrudin Rangoonwala; Gilles Dagenais; Hertzel Gerstein; Salim Yusuf
- Web page: https://patentgrep.com/patent/US20080287403A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for the prevention or reduction of the risk of diabetic complications in a diabetic patient with an increased cardiovascular risk and no evidence of left ventricular dysfunction or heart failure, which comprises administering to the patient an effective amount of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin.

### Claim 17 (depends on 16)

A method according to claim 16, where the diabetic complication is overt nephropathy, new microalbuminuria or the need for laser therapy or dialysis.

### Claim 18 (depends on 16)

A method according to claim 16, where diabetes is insulin-dependent diabetes mellitus.

### Claim 19 (depends on 16)

A method according to claim 16, where diabetes is non-insulin-dependent diabetes mellitus.

### Claim 20 (depends on 16)

A method according to claim 16, where the patient has at least one other risk factor.

### Claim 21 (depends on 20)

A method according to claim 20, where the other risk factor is current or previous hypertension, elevated total cholesterol, low HDL cholesterol, current cigarette smoking, known microalbuminuria or previous vascular disease.

### Claim 22 (depends on 16)

A method according to claim 16, where the patient is non-hypertensive.

### Claim 23 (depends on 16)

A method according to claim 16, where the patient is older than 55 years.

### Claim 24 (depends on 16)

A method according to claim 16, where the inhibitor of the renin-angiotensin system is an angiotensin converting enzyme inhibitor, an angiotensin II antagonist, or a pharmaceutically acceptable derivative of any of these.

### Claim 25 (depends on 24)

A method according to claim 24, where the angiotensin converting enzyme inhibitor is omapatrilat, MDL100240, alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat and spirapril or a pharmaceutically acceptable derivative thereof.

### Claim 26 (depends on 25)

A method according to claim 25, where the angiotensin converting enzyme inhibitor is ramipril or ramiprilat.

### Claim 27 (depends on 24)

A method according to claim 24, where the angiotensin II antagonist is saralasin acetate, candesartan cilexetil, valsartan, candesartan, losartan potassium, eprosartan, irbesartan, tasosartan, or telmisartan or a pharmaceutically acceptable derivative thereof.

### Claim 28 (depends on 25)

A method according to claim 25, where ramipril or ramiprilat or a pharmaceutically acceptable derivative thereof is used together with a cholesterol lowering agent.

### Claim 29 (depends on 28)

A method according to claim 28, where the cholesterol lowering agent is a statin.

### Claim 30 (depends on 29)

A method according to claim 29, where the statin is lovastatin, pravastatin, simvastatin or fluvastatin.

### Claim 31 (depends on 30)

A method according to claim 30, where the statin is pravastatin.

### Claim 32 (depends on 30)

A method according to claim 30, where the statin is simvastatin.

### Claim 33 (depends on 16)

A method according to claim 16, where the antihypertensive is a calcium channel blocker or a beta blocker.
